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Autoimmune encephalitides are a group of syndromes that may
present with subacute onset of disorientation, personality changes,
memory loss and most prominently seizures. Earlier reports of this
entity were from patients with paraneoplastic limbic encephalitis,
however autoimmune etiologies have also been described in
patients with non-paraneoplastic encephalitis [1].
The Alpha 3 ganglionic acetylcholine receptor autoantibody
(a3-AChR Ab) mainly causes autoimmune dysautonomia that is
either subacute or insidious in onset. A direct relationship
betweenantibody titer and severity of dysautonomia occurs in both
experimental animals and patients [2]. Most of these cases have
been paraneoplastic (mainly adenocarcinomas) however a few cases
have been linked to other autoimmune disorders such as systemic
lupus erythematosus (SLE) and Sjogren’s syndrome. Patients who
are seropositive for a3-AChR Ab may present with less common
neurological manifestations such as peripheral neuropathies,
encephalopathy and subacute neuropsychiatric presentations.
This report presents a unique case of refractory new-onset
status epilepticus associated with a3-AChR antibody which
responded to immunotherapy.
2. Case illustration
An 82-year-old lady presented to the emergency room with a
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and currently in remission. While in the emergency room, she was
witnessed to have a 1 min generalized tonic–clonic seizure with
left-sided gaze deviation. The convulsions were aborted with
2 mg of intravenous (IV) lorazepam but she continued to have
forced eye deviation to the left and residual left arm weakness.
Electroencephalogram (EEG) with video monitoring showed non-
convulsive status epilepticus (NCSE) originating from the right
temporal region. She was treated with IV lorazepam, and then
subsequently levetiracetam and lacosamide were administered
which successfully terminated the NCSE though there was
residual lateralized periodic discharges (LPDs) over the right
temporal region (Fig. 1A).
An MRI of the brain did not show any signiﬁcant T2 signal
changes or enhancement. A lumbar puncture was performed and
the cerebrospinal ﬂuid (CSF) was remarkable for 7/high power
ﬁeld nucleated cells (84% lymphocytes) and 94 mg/dL of protein.
CSF gram stain and polymerase chain reaction for Herpes
simplex virus were negative. Her serum was remarkable for
an elevated erythrocyte sedimentation rate (83 mm/h) and
elevated C-reactive protein (56.2 mg/L). Serum autoimmune
workup revealed a positive anti-nuclear antibody (1:80 titer).
Serum electrophoresis with immunoﬁxation showed IgG lambda
band in low concentration. Further paraneoplastic work-up
including anti-glutamic acid decarboxylase, N-methyl-D-aspar-
tate, voltage-gated potassium channel, anti-thyroid peroxidase
and thyroglobulin antibodies were negative. Her serum levels of
ganglionic acetylcholine receptor antibody against a3 subunit
titer returned positive at 0.11 nmol/L (normal <0.02 nmol/L).
Other radiological investigations for occult malignancies were
negative.
Her clinical improvement was very gradual and by day 10,
the patient had recovered most of her strength but would
Fig. 1. Electroencephalographic changes at various stages of clinical course. (A) On
presentation. Right temporal LPDs (arrow); (B) right temporal non-convulsive
status epilepticus, prior to steroid initiation; and (C) after 5 days of steroids, EEG
shows diffuse background slowing and residual right temporoparietal discharges
(arrow).
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show right hemisphere LPDs without evolution. On day 21, she
developed recurrent clinical seizures, which were treated with
higher doses of her previous AEDs (lacosamide 200 mg twice
daily; levetiracetam 1000 mg twice daily). However, on hospital
day 30 she developed NCSE over right temporal region which was
again aborted with IV lorazepam and phenytoin (loading dose of
20 mg/kg; subsequently 300 mg daily) was added to her previous
AED regimen. Due to her ﬂuctuating levels of consciousness,
inability to follow commands, unremitting right temporal LPDs
on EEG resistant to AED’s (Fig. 1B) and concern for autoimmune
encephalitis, she was started on a 5 day course of IV
methylprednisolone, followed by oral prednisone. Five days
after the initiation of steroids, the LPDs disappeared and were
replaced by focal discharges over the right temporoparietal
region (Fig. 1C). The patient began to improve a few days after
initiating treatment and after a week, she regained full strength
in all her extremities and was able to follow simple commands. At
the time of discharge, she had near complete cognitive recovery
and normal strength in her extremities.3. Discussion
Our patient presented with new onset refractory NCSE of
autoimmune etiology that was associated with a3-AChR Ab. A
retrospective study for neurological, oncological and serological
associations of a3-AChR Ab seropositivity conducted at Mayo
clinic [2] showed that neurological presentations were directly
proportional to antibody titers. Antibody values of 1.00 nmol/L or
higher were associated with symptoms of dysautonomia. Medium
antibody titers of 0.10–0.99 presented with more diverse
neurological symptoms, which included peripheral neuropathies
(36%), dysautonomia (20%, usually limited) and encephalopathy
(30%). Low antibody titers of 0.03–0.09 presented mostly with non-
autoimmune neurological disorders or no neurological disorder.
Malignancies, either active or by history have been identiﬁed as the
most common etiology associated with seropositive a3-AChR Ab.
Adenocarcinomas are the most common to be identiﬁed.
There has been only one previously reported case of seizures
secondary to a3-AChR Ab autoimmune disease, but this patient did
not respond to immunotherapy with intravenous steroids and IVIG
[3]. Even with antibody titers in the low-medium range, our
patient presented with new onset refractory status epilepticus that
did not respond to standard AED treatment and eventually
responded (clinically and electrographically) to steroids. Interest-
ingly, our patient did not have any clinical manifestations of
dysautonomia but this may have been due to the moderate
antibody titers present.
No single speciﬁc pattern on EEG has been reported to coincide
with limbic encephalitis (LE) [4]. Our patient had multiple, focal
recurrent seizures and NCSE as well as prolonged focal LPDs with
alteration of consciousness despite aggressive AED treatment. Her
clinical course and CSF ﬁndings were highly suspicion for
autoimmune-mediated epilepsy. Eventual treatment with immu-
nosuppressant led to improvement in patient’s clinical condition.
To our knowledge, no EEG changes have been reported in patients
associated with a3-AChR Ab LE in the literature.
4. Conclusion
This is the ﬁrst reported case of new onset refractory status
epilepticus linked to a3-AChR Ab that responded to immunother-
apy with steroids. A combination of oral steroids and AEDs may be
beneﬁcial in the long-term management of these patients. The
diagnosis of autoimmune disease in new onset epilepsy or status
epilepticus requires a high level of suspicion. Work-up for
autoimmune etiology should be considered in patients with
recurrent or intractable seizures, AED resistance, personal or
family history of autoimmune disease and history of cancer.
Further insight on the duration of immunotherapy is required for
prognostication and improved outcome in these patients.
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